SCM
DOVA

Stonepine Capital Management’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Stonepine Capital Management’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,900
Closed -$145K – 33
2018
Q3 		$145K Buy
+6,900
New +$164K 0.08% 31
2018
Q2 		– Sell
-184,000
Closed -$4.99M – 36
2018
Q1 		$4.99M Buy
+184,000
New +$5.5M 2.67% 12

Other funds holding DOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Stonepine Capital Management's DOVA Position: Q4 2018 in Review

Stonepine Capital Management sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2018, closing a stake of 6,900 shares — an estimated $145K sold.

Stonepine Capital Management first reported a position in DOVA in Q1 2018 and held it in 2 quarters. The position peaked at $4.99M in Q1 2018. 58 funds tracked by Wall St. Rank hold DOVA as of Q4 2018.

  • Stonepine Capital Management reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Stonepine Capital Management sold 6,900 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $145K.
  • Stonepine Capital Management first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Stonepine Capital Management's Dova Pharmaceuticals, Inc. Common Stock position peaked at $4.99M in Q1 2018.
  • 58 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Stonepine Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.